High Court Gives Stryker Second Shot At Enhanced Damages
This article was originally published in The Gray Sheet
Executive Summary
The court’s ruling likely expands the circumstances under which patent-holders may be awarded enhanced damages by eliminating a strict test that had been imposed by the Federal Circuit.
You may also be interested in...
Stryker-Zimmer Case Sets Up Tech Industry, Government Clash On Patent Damages Issue
In a case going before the Supreme Court in less than three weeks, Stryker is asking the court to broaden the circumstances under which patent damages may be tripled, a position the Obama administration appears to support but one that is getting pushback from tech firms, and at least one device-maker, Medtronic.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.